Barclays PLC Annexon, Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Annexon, Inc. stock. As of the latest transaction made, Barclays PLC holds 74,900 shares of ANNX stock, worth $361,767. This represents 0.0% of its overall portfolio holdings.
Number of Shares
74,900
Previous 185,331
59.59%
Holding current value
$361,767
Previous $841,000
36.27%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ANNX
# of Institutions
138Shares Held
87.3MCall Options Held
2.54MPut Options Held
556K-
Bain Capital Life Sciences Investors, LLC Boston, MA8.7MShares$42 Million9.43% of portfolio
-
Satter Management Co., L.P.7.41MShares$35.8 Million59.29% of portfolio
-
Bvf Inc San Francisco, CA7MShares$33.8 Million1.5% of portfolio
-
Redmile Group, LLC San Francisco, CA5.5MShares$26.6 Million1.56% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.16MShares$24.9 Million0.09% of portfolio
About Annexon, Inc.
- Ticker ANNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,617,700
- Market Cap $230M
- Description
- Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...